Long‐term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis

OBJECTIVE: To assess the long‐term efficacy and safety of erenumab in the subgroup of patients with chronic migraine (CM) in whom prior preventive treatments had failed (TF) (≥1, ≥2, and ≥3 TF medication categories) and never failed (preventive naïve or prior preventive treatments had not failed), u...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashina, Messoud, Tepper, Stewart J., Brandes, Jan Lewis, Reuter, Uwe, Boudreau, Guy P., Weatherall, Mark, Gantenbein, Andreas R., Doležil, David, Klatt, Jan, Wang, Andrea, Karanam, Ananda Krishna, Cheng, Sunfa, Mikol, Daniel D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324861/
https://www.ncbi.nlm.nih.gov/pubmed/35593783
http://dx.doi.org/10.1111/head.14313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324861/
https://www.ncbi.nlm.nih.gov/pubmed/35593783
http://dx.doi.org/10.1111/head.14313

Ejemplares similares